Embed Notice

HTML Code

<blockquote style="position: relative; padding-left: 55px;"><section><a href="https://mstdn.social/users/erictopol/statuses/112527526392167502">Eric Topol (erictopol@mstdn.social)'s status on Thursday, 30-May-2024 16:56:49 JST</a><a href="https://mstdn.social/@erictopol" title="erictopol@mstdn.social"><img src="https://gnusocial.jp/avatar/28946-48-20221117011128.webp" width="48" height="48" alt="Eric Topol" style="position: absolute; left: 0; top: 0;">Eric Topol</a></section><article><p>What if there was an antibiotic that doesn't disrupt the gut microbiome?<br>There is now.<br>A discovery published  at Nature today<br><a href="https://nature.com/articles/s41586-024-07502-0" rel="nofollow noreferrer">https://nature.com/articles/s41586-024-07502-0</a></p></article><footer><a rel="bookmark" href="https://gnusocial.jp/conversation/3165504#notice-6261231">In conversation</a><time datetime="2024-05-30T16:56:49+09:00" title="Thursday, 30-May-2024 16:56:49 JST">about 6 months ago</time> <span>from <span><a href="https://mstdn.social/@erictopol/112527526392167502" rel="external" title="Sent from mstdn.social via ActivityPub">mstdn.social</a></span></span><a href="https://mstdn.social/@erictopol/112527526392167502">permalink</a><h4>Attachments</h4><ol><li><label><a rel="external" href="https://gnusocial.jp/attachment/2711317">Untitled attachment</a></label><br><a href="https://media.mstdn.social/media_attachments/files/112/527/526/144/210/103/original/57b3ab38d5b63402.jpeg" rel="external">https://media.mstdn.social/media_attachments/files/112/527/526/144/210/103/original/57b3ab38d5b63402.jpeg</a></li><li><article><header><div>Domain not in remote thumbnail source whitelist: media.springernature.com</div><h5><a href="https://www.nature.com/articles/s41586-024-07502-0?error=cookies_not_supported&amp;code=8c67f9e1-6f92-4275-8464-b0539207d44a">A Gram-negative-selective antibiotic that spares the gut microbiome - Nature</a></h5><div> from <span>Hergenrother, Paul J.</span></div></header><div>Lolamicin, a novel antibiotic developed from a pyridinepyrazole precursor, exhibits potent activity against a broad range of Gram-negative multidrug-resistant clinical isolates, and good efficacy in mouse models of infection without inducing gut dysbiosis.</div><footer></footer></article></li></ol></footer></blockquote>

Corresponding Notice

Embed this notice
Eric Topol (erictopol@mstdn.social)'s status on Thursday, 30-May-2024 16:56:49 JST Eric Topol
What if there was an antibiotic that doesn't disrupt the gut microbiome?
There is now.
A discovery published at Nature today
https://nature.com/articles/s41586-024-07502-0
In conversationabout 6 months ago from mstdn.socialpermalink
Attachments
1. Untitled attachment
  https://media.mstdn.social/media_attachments/files/112/527/526/144/210/103/original/57b3ab38d5b63402.jpeg
2. Domain not in remote thumbnail source whitelist: media.springernature.com
  A Gram-negative-selective antibiotic that spares the gut microbiome - Nature
  from Hergenrother, Paul J.
  Lolamicin, a novel antibiotic developed from a pyridinepyrazole precursor, exhibits potent activity against a broad range of Gram-negative multidrug-resistant clinical isolates, and good efficacy in mouse models of infection without inducing gut dysbiosis.

Public

Embed Notice

HTML Code

Corresponding Notice